Results 41 to 50 of about 50,320 (220)

Anti-inflammatory Effect of Spironolactone on Human Peripheral Blood Mononuclear Cells

Journal of Pharmacological Sciences, 2006
.: We evaluated the effect of alacepril, CV-11974, and spironolactone on the production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) in cultured human peripheral blood mononuclear cells stimulated with angiotensin
Miura Ryuzea, Nakamura Kazufumi, Miura Daiji, Miura Aya, Hisamatsu Kenichi, Kajiya Masahito, Nagase Satoshi, Morita Hiroshi, Kusano Kengo Fukushima, Ohe Tohru, Ishihara Kazuhiko   +10 more
doaj   +1 more source

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Contemporary Clinical Trials Communications, 2020
Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model.
Alkomiet Hasan, Astrid Roeh, Stefan Leucht, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K. Kirchner, Irina Papazova, Lisa Löhrs, Elias Wagner, Isabel Maurus, Wolfgang Strube, Moritz J. Rossner, Michael C. Wehr, Ingrid Bauer, Stephan Heres, Claudia Leucht, Peter M. Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Susanne Karch, Silvia Egert-Schwender, Beate Schossow, Philipp Rothe, Peter Falkai   +25 more
doaj   +1 more source

Mineralocorticoid receptor blockade during a rat's first violent encounter inhibits its subsequent propensity for violence. [PDF]

, 2013
In individuals naive to serious conflict in an unfamiliar environment, violence has long-lasting effects on subsequent aggressive behavior. This effect of the stressful experience of a first violent conflict occurs in victims as well as offenders.
Haller, József, Kloet, E. R., Kruk, M. R., Meelis, W.   +3 more
core   +1 more source

Spironolactone in Alcohol Use Disorder (SAUD): Introduction to an ongoing double-blind, placebo-controlled, ascending dose, Phase 1b study

European Psychiatry
Introduction Efforts are critically needed to increase the armamentarium of options that clinicians can use to treat patients with alcohol use disorder (AUD).
A. Leko, M. Farokhnia, S. T. Weiss, C. A. Blake, L. A. Farinelli, L. Leggio   +5 more
doaj   +1 more source

Medical treatment of ascites in cirrhosis [PDF]

, 1993
Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired cardiovascular or respiratory function and potential for infection. Treatment of ‘simple’ ascites (moderate fluid accumulation, serum albumin
Alexander L. Gerbes, Bernardi, Bichet, Bosch, Broekhuysen, Caramelo, Conn, DiBona, Epstein, Faloon, Fogel, Fuller, Ganger, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Ginès, Gregory, Guarner, Henriksen, Hoermann, Jüngst, Karnad, Keppler, Laffi, Lenz, Levy, Moore, Perez-Ayuso, Petrillo, Pockros, Ring-Larsen, Schrier, Schölmerich, Shear, Sherlock   +41 more
core   +1 more source

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms [PDF]

, 2014
Aim In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II ...
Akehurst, R., Cowie, M.R., Krum, H., Lee, D., McMurray, J.J.V., Pitt, B., van Veldhuisen, D.J., Vincent, J., Wilson, K., Zannad, F.   +9 more
core   +3 more sources

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P., Antohi, Elena-Laura, Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Iliescu, Vlad Anton, Maggioni, Aldo P., Mebazaa, Alexandre, Pang, Peter S.   +8 more
core   +1 more source

Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. [PDF]

, 2003
The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone ...
Kirim, Sinan, Sert, Murat, Tetiker, Tamer   +2 more
core   +1 more source

Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment

Journal of Ophthalmology, 2018
Purpose. To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). Methods.
Jin Young Kim, Ju Byung Chae, Jisoo Kim, Dong Yoon Kim   +3 more
doaj   +1 more source

Spironolactone for the treatment of acne in women, a retrospective study of 110 patients

International Journal of Women's Dermatology, 2017
Background: There is limited evidence on the safety and efficacy of spironolactone in the treatment of women with acne. Thus, for many dermatologists spironolactone remains an alternative rather than a mainstay treatment for female patients with acne ...
J.W. Charny, BS, J.K. Choi, MD, PhD, W.D. James, MD   +2 more
doaj   +1 more source